January 20, 2015, 10:17pm
This new medication looks interesting:
Hungarian drug maker Richter and its partner Actavis announced that the third phase of trials for the anti-psychotic drug Cariprazine was successful.
Cariprazine is designed to treat relapse in schizophrenia patients. During Phase III, each of the subjects given the drug showed positive results, Reuters reported.
The drug was associated with a 55 percent reduction in the risk of relapse, the companies said in a statement on Tuesday.
To test the effectiveness of Cariprazine, 101 patients were given three to nine milligrams of the drug each day. Ninety-nine other were given a placebo.
Cariprazine, sold under the brand names Vraylar in the United States and Reagila in Europe, is an atypical antipsychotic which is used in the treatment of schizophrenia and bipolar mania. It acts primarily as a D3 receptor and D2 receptor partial agonist, with high selectivity for the D3 receptor. Positive Phase III study results were published for schizophrenia and mania in early 2012, and for bipolar disorder I depression from a Phase II trial in 2015. It is also potentially useful Rights are ...
Read the full story here:
Gedeon Richter (23 September 1872 – 30 December 1944) was a Hungarian pharmacist, founder of Gedeon Richter plc and a pioneer of the modern Hungarian pharmaceutical industry. Richter was born in Ecséd, Hungary, but due to the death of his parents, from 1873 he grew up in Gyöngyös. From 1890 he worked there as a trainee pharmacist. In 1895 Richter completed his degree in pharmacology with a high mark at the Budapest University. Two years later, he travelled to several European pharmacies and pha...
Actavis Generics (formerly known as Watson Pharmaceuticals and Actavis PLC, prior to the acquisition of Allergan Inc) is a global pharmaceutical company focused on developing, manufacturing and commercializing branded pharmaceuticals, generic and over-the-counter medicines, and biologic products. Actavis has a commercial presence across approximately 100 countries. The company has global headquarters in Dublin, Ireland and administrative headquarters in Parsippany-Troy Hills, New Jersey, Unite Ac...
55% doesn’t sound all that good
January 20, 2015, 11:02pm
Perhaps not - but I’m sure if you’re in the 55% who don’t relapse you think its great.
Is it 55% per year though?
CBD natural anti psychotic, all you need…
January 21, 2015, 12:00pm
This new drug is being tested for depression - It is just going to be another activating, anxiety inducing new atypical.
I cannot wait for the CBD antipsychotics to be coming out - As a person with a lot of anxiety, the newer atypicals that are better for you body, are worse for my mind